SUNNYVALE, Calif. , Feb. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference , which takes place February 15-17, 2022 .
Record Revenue For Second Quarter Fiscal 2022 SUNNYVALE, Calif. , Jan. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2022 ended December 31, 2021 . Second Quarter Fiscal 2022 Summary Record net revenue of $116.3
SUNNYVALE, Calif. , Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022. Management will host a conference call to review the
- Trigeminal neuralgia, a persistent neurological disorder, is described by some patients as the most excruciating pain human beings can experience(1) - The approval expands global patient access to the CyberKnife System, an effective, non-invasive treatment alternative to surgery SUNNYVALE, Calif.
7,000 Patient Single Institution Analysis Shows Safety, Versatility and Increasing Use of the Advanced Radiotherapy Platform Over a 20-Year Timeframe SUNNYVALE, Calif. , Nov. 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that more than two
Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced its participation in Stifel's 2021 Virtual Healthcare Conference . The management team is scheduled to present on
Record Revenue First Quarter Fiscal 2022 SUNNYVALE, Calif. , Nov. 3, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 . First Quarter Fiscal 2022 Summary Record net revenue of $107.4 million
SUNNYVALE, Calif. , Oct. 25, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast
SUNNYVALE, Calif. , Oct. 21, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), today announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021 . Accuray is currently finalizing its financial results for the first quarter of fiscal 2022.
Showcases Multiple Forward-Looking Radiotherapy Solutions Designed to Enhance the Treatment Experience for Medical Care Teams and Their Patients SUNNYVALE, Calif. , Oct. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
